Cencora, Inc. (NYSE:COR) on Wednesday reported third-quarter 2025 sales increased 8.7% to $80.66 billion, beating the ...

Q3 2025 Management View Robert P. Mauch, President and CEO, opened by highlighting "Cencora delivered strong performance with adjusted operating income growth of 21% and adjusted diluted EPS growth of ...

U.S. drug distributor Cencora raised its annual profit forecast on Wednesday after posting quarterly earnings that topped Wall Street estimates, buoyed by surging demand for specialty therapies and ...

Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 third quarter ended June 30, 2025, revenue increased 8.7 ...

COR benefits from strong specialty and GLP-1 demand, but Q3 results may face pressure from international weakness.

Cencora, Inc. ( NYSE: COR) Q3 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Bennett S. Murphy - Senior VP, Head of Investor Relations & Treasury James F. Cleary - Executive VP & CFO Robert P ...

Shares of Cencora Inc. COR shed 2.93% to $283.78 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.73% to 6,345.06 and ...

CONSHOHOCKEN, Pa. - On Wednesday, Cencora, Inc. (NYSE: COR) reported third-quarter fiscal 2025 results that exceeded analyst expectations, with adjusted earnings per share of $4.00 beating the ...

Steve Collis’ three decades of experience at a major drug distributor could prove helpful for Elevance as it continues to ...

Shares of Cencora Inc. COR slipped 1.96% to $286.08 Thursday, on what proved to be an all-around rough trading session for ...